Skip to main content
. Author manuscript; available in PMC: 2015 Dec 1.
Published in final edited form as: Cancer Res. 2014 Oct 6;74(23):7048–7059. doi: 10.1158/0008-5472.CAN-14-1470

Figure 2.

Figure 2

Rapamycin and JQ1 combination treatment reduces Pten null T-ALL disease burden and LICs. A, measurement of splenic mass and quantitation of blast and LIC populations in bone marrow of Pten null T-ALL mice by flow cytometric analysis after 7 day treatment in vivo. B, Kaplan-Meier survival curve representing morbidity of NSG recipients transplanted with 104 and 103 cell doses of treated bone marrow (BM) cells. C, fraction of secondary recipients that developed leukemia when transplanted with limiting dilutions of rapamycin or rapamycin and JQ1 combination treated donor cells, and logarithmic plot and limiting dilution analysis to calculate LIC frequency after rapamycin and JQ1 combination treatment. LIC frequency after 7 day rapamycin and JQ1 combination treatment is ~1/200,000. Data in A are represented as mean ± SEM (*p<0.05, **p<0.01, ***p<0.001).